IBDEI1XW ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,34428,1,4,0)
 ;;=4^D86.89
 ;;^UTILITY(U,$J,358.3,34428,2)
 ;;=^5002453
 ;;^UTILITY(U,$J,358.3,34429,0)
 ;;=D86.3^^192^1998^52
 ;;^UTILITY(U,$J,358.3,34429,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34429,1,3,0)
 ;;=3^Sarcoidosis of Skin
 ;;^UTILITY(U,$J,358.3,34429,1,4,0)
 ;;=4^D86.3
 ;;^UTILITY(U,$J,358.3,34429,2)
 ;;=^5002445
 ;;^UTILITY(U,$J,358.3,34430,0)
 ;;=D86.9^^192^1998^53
 ;;^UTILITY(U,$J,358.3,34430,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34430,1,3,0)
 ;;=3^Sarcoidosis,Unspec
 ;;^UTILITY(U,$J,358.3,34430,1,4,0)
 ;;=4^D86.9
 ;;^UTILITY(U,$J,358.3,34430,2)
 ;;=^5002454
 ;;^UTILITY(U,$J,358.3,34431,0)
 ;;=M35.01^^192^1998^54
 ;;^UTILITY(U,$J,358.3,34431,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34431,1,3,0)
 ;;=3^Sicca Syndrome w/ Keratoconjunctivitis
 ;;^UTILITY(U,$J,358.3,34431,1,4,0)
 ;;=4^M35.01
 ;;^UTILITY(U,$J,358.3,34431,2)
 ;;=^5011787
 ;;^UTILITY(U,$J,358.3,34432,0)
 ;;=M35.02^^192^1998^55
 ;;^UTILITY(U,$J,358.3,34432,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34432,1,3,0)
 ;;=3^Sicca Syndrome w/ Lung Involvement
 ;;^UTILITY(U,$J,358.3,34432,1,4,0)
 ;;=4^M35.02
 ;;^UTILITY(U,$J,358.3,34432,2)
 ;;=^5011788
 ;;^UTILITY(U,$J,358.3,34433,0)
 ;;=M35.03^^192^1998^56
 ;;^UTILITY(U,$J,358.3,34433,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34433,1,3,0)
 ;;=3^Sicca Syndrome w/ Myopathy
 ;;^UTILITY(U,$J,358.3,34433,1,4,0)
 ;;=4^M35.03
 ;;^UTILITY(U,$J,358.3,34433,2)
 ;;=^5011789
 ;;^UTILITY(U,$J,358.3,34434,0)
 ;;=M35.09^^192^1998^57
 ;;^UTILITY(U,$J,358.3,34434,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34434,1,3,0)
 ;;=3^Sicca Syndrome w/ Oth Organ Involvement
 ;;^UTILITY(U,$J,358.3,34434,1,4,0)
 ;;=4^M35.09
 ;;^UTILITY(U,$J,358.3,34434,2)
 ;;=^5011791
 ;;^UTILITY(U,$J,358.3,34435,0)
 ;;=M35.04^^192^1998^58
 ;;^UTILITY(U,$J,358.3,34435,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34435,1,3,0)
 ;;=3^Sicca Syndrome w/ Tubulo-Interstitial Nephropathy
 ;;^UTILITY(U,$J,358.3,34435,1,4,0)
 ;;=4^M35.04
 ;;^UTILITY(U,$J,358.3,34435,2)
 ;;=^5011790
 ;;^UTILITY(U,$J,358.3,34436,0)
 ;;=M35.00^^192^1998^59
 ;;^UTILITY(U,$J,358.3,34436,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34436,1,3,0)
 ;;=3^Sicca Syndrome,Unspec
 ;;^UTILITY(U,$J,358.3,34436,1,4,0)
 ;;=4^M35.00
 ;;^UTILITY(U,$J,358.3,34436,2)
 ;;=^5011786
 ;;^UTILITY(U,$J,358.3,34437,0)
 ;;=M32.10^^192^1998^62
 ;;^UTILITY(U,$J,358.3,34437,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34437,1,3,0)
 ;;=3^Systemic Lupus Erythematosus,Unspec Organ/System Involvement
 ;;^UTILITY(U,$J,358.3,34437,1,4,0)
 ;;=4^M32.10
 ;;^UTILITY(U,$J,358.3,34437,2)
 ;;=^5011753
 ;;^UTILITY(U,$J,358.3,34438,0)
 ;;=M32.9^^192^1998^61
 ;;^UTILITY(U,$J,358.3,34438,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34438,1,3,0)
 ;;=3^Systemic Lupus Erythematosus,Unspec
 ;;^UTILITY(U,$J,358.3,34438,1,4,0)
 ;;=4^M32.9
 ;;^UTILITY(U,$J,358.3,34438,2)
 ;;=^5011761
 ;;^UTILITY(U,$J,358.3,34439,0)
 ;;=M34.2^^192^1998^63
 ;;^UTILITY(U,$J,358.3,34439,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34439,1,3,0)
 ;;=3^Systemic Sclerosis Induced by Drug/Chemical
 ;;^UTILITY(U,$J,358.3,34439,1,4,0)
 ;;=4^M34.2
 ;;^UTILITY(U,$J,358.3,34439,2)
 ;;=^5011780
 ;;^UTILITY(U,$J,358.3,34440,0)
 ;;=M34.81^^192^1998^64
 ;;^UTILITY(U,$J,358.3,34440,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34440,1,3,0)
 ;;=3^Systemic Sclerosis w/ Lung Involvement
 ;;^UTILITY(U,$J,358.3,34440,1,4,0)
 ;;=4^M34.81
 ;;^UTILITY(U,$J,358.3,34440,2)
 ;;=^5011781
 ;;^UTILITY(U,$J,358.3,34441,0)
 ;;=M34.82^^192^1998^65
 ;;^UTILITY(U,$J,358.3,34441,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34441,1,3,0)
 ;;=3^Systemic Sclerosis w/ Myopathy
